Ann: Dr Philip Currie Joins ResApp's Scientific Advisory Board, page-94

@Dicebat - Thanks for the kind words.

Let's talk constructive and discuss this stock based on facts .

1 - Based on the last Trial we know RAP can't go for FDA, TGA, CE approval..

2. Second Trial is the only option at hospital as no other trial can assist with getting regulatory approval and without that not possible to commercialize the app and hence no revenue.

3. If they tweak the alogorithm then it will start of square one because changes can solve one problem and intriduce another.

4. Trial will take about 7/8 months as last time and each trial cost is approx 2m... so fund will be dispensed lavishly to conduct 3 trials in parallel -

DX, Adult and MSF trial..

5. This will raise question of cap raise down the track

We all know crash from 55c to 5.5 is because we have no revenue but lucky to have few millions in the bank account to be able to go for second trial provided hospitals agree. Let's see if all 3 hospitals agree or not first..

I am open to criticism from anyone on this so please feel free to reply to this . I wish if management spend time focusing on the product instead of answering phone calls from us all day long.. Anyways we learnt the lesson. In any other company if this would have happen then some people would have been shown the door.